WO2012115641A1 - Compositions de pro-insuline lis-pro et procédés de production d'analogues d'insuline lis-pro à partir de celles-ci - Google Patents

Compositions de pro-insuline lis-pro et procédés de production d'analogues d'insuline lis-pro à partir de celles-ci Download PDF

Info

Publication number
WO2012115641A1
WO2012115641A1 PCT/US2011/025934 US2011025934W WO2012115641A1 WO 2012115641 A1 WO2012115641 A1 WO 2012115641A1 US 2011025934 W US2011025934 W US 2011025934W WO 2012115641 A1 WO2012115641 A1 WO 2012115641A1
Authority
WO
WIPO (PCT)
Prior art keywords
lis
pro
proinsulin
arg
insulin
Prior art date
Application number
PCT/US2011/025934
Other languages
English (en)
Inventor
Ronald E. ZIMMERMAN
David John STOKELL
Michael Patrick AKERS
Original Assignee
Elona Biotechnologies
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Elona Biotechnologies filed Critical Elona Biotechnologies
Priority to PCT/US2011/025934 priority Critical patent/WO2012115641A1/fr
Publication of WO2012115641A1 publication Critical patent/WO2012115641A1/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/62—Insulins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics

Definitions

  • the invention relates to compositions and preparations that comprise Lis-Pro proinsulin, and in particular Lis-Pro proinsulin with modified C-peptide sequences.
  • the invention also relates to methods of manufacture for manufacturing Lis-Pro insulin analogs from modified proinsulin sequences.
  • Insulin is a hormone that regulates glucose metabolism in animals.
  • Insulin is a polypeptide hormone secreted by beta-cells of the pancreas. This hormone is made up of two polypeptide chains, an A-chain of 21 amino acids, and a B-chain of 30 amino acids. These two chains are linked to one another in the mature form of the hormone by two interchain disulphide bridges. The A-chain also features one intra-chain disulphide bridge.
  • Insulin analogs are altered forms of native insulin that are available to the body for performing the same action as native insulin.
  • a specific insulin analog known as Lis-Pro insulin has also been described in US Pat. Nos. 5,474,978 and 5,504,188. This analog is used in the treatment of diabetes.
  • Lis-Pro insulin is characterized as a short acting insulin analog, which, when combined with an insulin pump, allows for better blood glucose stability without the risk of hyperglycemia.
  • This Lis-Pro insulin analog has been available commercially as HUMALOG® (Eli Lilly).
  • HUMALOG® is an insulin analog wherein the molecule includes a Lys(B 28 )- Pro(B 29 ) amino acid sequence in place of the native insulin Pro(B 28 )-Lys(B 29 ).
  • HUMALOG® is an injectable, fast-acting insulin.
  • Proinsulin is a molecule comprised of a prepeptide of 24 amino acids, followed by the B-chain peptide, a C-peptide of 35 amino acids, and the A-chain peptide.
  • the C-peptide of this precursor insulin molecule (“proinsulin”) contains the two amino acids, lysine-arginine (KR) at its carboxy end (where it attaches to the A-chain), and the two amino acids, arginine-arginine (RR) at its amino end (where it attaches to the B-chain).
  • KR lysine-arginine
  • RR arginine-arginine
  • the C-peptide is cleaved away from the peptide so as to leave the A-chain and the B-chain connected directly to one another in its active form.
  • a third method utilizes yeast, especially Saccharomyces cerevisiae, to secrete the insulin precursor into the medium (Thim, et al. (1986), P.N.A.S., USA., 83: 6766-6770).
  • Chance et al. reported a process for preparing insulin by producing each of the A and B chains of insulin in the form of a fusion protein by culturing E. coli that carries a vector compromising a DNA encoding the fusion protein, cleaving the fusion protein with cyanogen bromide to obtain the A and the B chains, sulfonating the A and B chains to obtain sulfonated chains, reacting the sulfonated B chain with an excess amount of the sulfonated A chain; and then purifying the resultant products to obtain insulin.
  • US Pat. No. 5,700,662 describes recombinant processes for producing various insulin analogs, including using the process of Chance et al. to produce Lis-Pro insulin analogs.
  • proinsulin is produced in the form of a fusion protein by culturing E. coli which carries a vector comprising a nucleic acid sequence (DNA) encoding for the fusion protein, cutting the fusion protein with cyanogen bromide to obtain proinsulin, sulfonating the proinsulin and separation of the sulfonated proinsulin, refolding the sulfonated proinsulin to form correct disulfide bonds, treating the refolded proinsulin with trypsin and carboxypeptidase B, and then purifying the resultant product to obtain insulin.
  • DNA nucleic acid sequence
  • the yield of the refolded proinsulin having correctly folded disulfide bonds is reported to sharply decrease as the concentration of the proinsulin increases. This is allegedly due to, at least among other reasons, misfolding of the protein, and some degree of polymerization being involved. Hence, the process entails the inconvenience of using laborious purification steps during the recovery of proinsulin.
  • Thim et al. reported a process for producing insulin in yeast, Saccharomyces cerevisiae. This process has the steps of producing a single chain insulin analog having a certain amino acid sequence by culturing Saccharomyces cerevisiae cells, and isolating insulin therefrom through the steps of: purification, enzyme reaction, acid hydrolysis and a second purification. This process, however, results in an unacceptably low yield of insulin.
  • Trypsin is a typical serine protease, and hydrolyses a protein or peptide at the carboxyl terminal of an arginine or lysine residue ⁇ Enzymes, pp. 261-262 (1979), ed. Dixon, M. & Webb, E. C. Longman Group Ltd., London).
  • This unwanted hydrolysis results in the unwanted Arg(Ao)-insulin byproduct, and typically constitutes about 10% of the reaction yield.
  • an additional purification step is required. The necessity of an additional purification step makes the process much more time consuming, and thus expensive, to use. Moreover, an additional loss of yield may be expected from the necessity of this additional purification step.
  • proinsulin constructs that do not have a conserved terminal dibasic amino acid sequence of the C-peptide region.
  • US Pat. No. 6,777,207 (Kjeldsen et al.) relates to a novel proinsulin peptide construct containing a shortened C-peptide that includes the two terminal amino acids, glycine-arginine or glycine-lysine at the carboxyl terminal end that connects to the A-chain of the peptide.
  • the B-chain of the proinsulin construct described therein has a length of 29 amino acids, in contrast to the native 30 amino acid length of the native B-chain in human insulin.
  • yeast provides a relatively low insulin yield, due to the intrinsically low expression levels of a yeast system as compared to E. coli.
  • the present invention provides processes for using a modified Lis-Pro proinsulin sequence to produce Lis-Pro insulin analogs.
  • the modified Lis-Pro proinsulin sequence has the formula
  • [0018] is a tag sequence containing one or more amino acids, preferably with a C- terminal Arg or Lys, or R ⁇ is absent with an Arg or Lys present prior to the start of the B chain;
  • (B ⁇ -B2 ) and (ArA 21 ) comprise amino acid sequences of native human insulin
  • B 28 is any amino acid other than Pro, preferably B 28 is Lys;
  • B 29 is any amino acid other than Lys or Arg, preferably B 29 is Pro;
  • B 30 is Thr
  • R 2 , R 3 and R 5 are Arg
  • R4 is any amino acid other than Gly, Lys or Arg or is absent, preferably Ala;
  • X is a sequence comprises one or more amino acids or is absent, provided that X is not EAEALQVGQVELGGGPGAGSLQPLALEGSLQ (SEQ ID NO: 2) and X does not comprise a C-terminal Gly, Lys, or Arg when R4 is absent; and
  • Re is a tag sequence containing one or more amino acids, preferably with a N- terminal Arg or Lys, or R 6 is absent.
  • [0027] in one aspect of the present invention is related to a process for producing Lis-Pro insulin analogs comprising the steps of culturing E. coli cells under conditions suitable for expression of a modified Lis-Pro proinsulin sequence of Formula I, disrupting the cultured E. coli cells to provide a composition comprising inclusion bodies containing the modified Lis-Pro proinsulin sequence, solubilizing the composition of inclusion bodies, and recovering Lis-Pro insulin analogs from the solubilized composition.
  • Another aspect of the present invention is related to a process for producing Lis-Pro insulin analogs comprising the steps of providing a modified Lis-Pro proinsulin sequence of Formula I, folding the modified Lis-Pro proinsulin sequence to provide a Lis-Pro proinsulin derivative peptide, enzymatically cleaving the Lis-Pro proinsulin derivative peptide to remove a connecting peptide and provide an intermediate solution comprising Lis-Pro insulin analog, and purifying the intermediate solution in a chromatography column wherein the Lis-Pro insulin analog is eluted using a buffer comprising n-propanol.
  • Another aspect of the present invention is related to a process for producing Lis-Pro insulin analogs comprising the steps of culturing transformed E. coli cells having modified Lis- Pro proinsulin sequence of Formula I under conditions suitable for expression of the modified Lis-Pro proinsulin sequence, disrupting said cultured E.
  • the coli cells to provide a composition comprising inclusion bodies containing the modified Lis-Pro proinsulin sequence, solubilizing said composition of inclusion bodies by adjusting the pH to at least 10.5, folding the modified Lis-Pro proinsulin sequence to provide a Lis-Pro proinsulin derivative peptide, enzymatically cleaving the Lis-Pro proinsulin derivative peptide to remove a connecting peptide and provide an intermediate solution comprising Lis-Pro insulin analog, and purifying the intermediate solution in a chromatography column.
  • the Lis-Pro insulin analog is eluted using a buffer comprising n-propanol.
  • FIG. 1 is a vector map of plasmid pTrcHis2A (Kan) with a Lis-Pro proinsulin gene insert.
  • FIG. 2a and FIG 2b present process flow schemes for the purification of Lis-Pro insulin analogs.
  • the present invention generally relates to the preparation of insulin analogs, specifically Lis-Pro insulin analog, from modified Lis-Pro proinsulin sequences.
  • Lis-Pro insulin analog comprises a modified B-chain having Lys(B 28 ) and Pro(B 29 ).
  • Modified Lis-Pro proinsulin sequences refer to a single-chain polypeptide that may be converted into human insulin or insulin analogs and comprise a connecting peptide (C -peptide) having at least one non-dibasic terminal amino acid sequence.
  • non-dibasic terminal amino acid sequences may comprise any amino acid except Lys or Arg-Arg ((any except R or K)R), and more preferably any amino acid except Gly, Lys, or Arg-Arg ((any except G, R, or K)R).
  • the terminal amino acid sequence may comprise Ala-Arg.
  • the positioning of these particular terminal amino acids in the C-peptide provides for an improved method for producing recombinant Lis-Pro insulin analog, having fewer steps, improved yields of the recombinant Lis- Pro insulin analog and less contaminating byproducts.
  • the process for producing Lis-Pro insulin analogs of the invention presents many advantages, among them the advantage of reducing and/or eliminating the presence of unwanted and contaminating cleavage by-products characteristic of conventional manufacturing processes for producing recombinant human Lis-Pro insulin in E. coll Previously undesirable by-products evident in yield mixtures using conventional methods of producing recombinant human insulin analogs included, by way of example, the production of an unwanted cleavage product, Arg(A 0 )- insulin analogs.
  • a highly efficient process for the production of recombinant human insulin analogs is presented that reduces and/or eliminates the presence of this and other unwanted and undesirable cleavage by-products, and that further presents the advantages of eliminating several time consuming, expensive, purification steps.
  • a process having fewer technician-assisted steps is thus devised, and illustrates the additional advantage of eliminating the degree of inconsistency and/or error associated with technician assisted steps in the manufacturing process.
  • the modified Lis-Pro proinsulin sequence of the present invention has a formula I:
  • R] is a tag sequence containing one or more amino acids, preferably with a C- terminal Arg or Lys, or Ri is absent with an Arg or Lys present prior to the start of the B chain;
  • (B!-B 27 ) and (A!-A 21 ) comprise amino acid sequences of native human insulin;
  • B 2 8 is any amino acid other than Pro, preferably B 28 is Lys;
  • B 2 9 is any amino acid other than Lys or Arg, preferably B 29 is Pro;
  • B 30 is Thr
  • R 2 , R 3 and R 5 are Arg
  • R4 is any amino acid other than Gly, Lys or Arg or is absent, preferably Ala;
  • X is a sequence comprising one or more amino acids, or is absent, provided that X is not EAEALQVGQVELGGGPGAGSLQPLALEGSLQ (SEQ ID NO: 2), and X does not comprise a C-terminal Gly, Lys, or Arg when R 4 is absent; and
  • R 6 is a tag sequence containing one or more amino acids, preferably with a N- terminal Arg or Lys, or R 6 is absent.
  • Ri or R ⁇ in the modified proinsulin of Formula I comprises a pre or post-peptide that may be a native pre-peptide or an N-terminal multiple His-tag sequence, or any other commercially available tag utilized for protein purification, e.g. DSBC, Sumo, Thioredein, T7, S tag, Flag Tag, HA tag, VS epitope, Pel B tag, Xpress epitope, GST, MBP, NusA, CBP, or GFP.
  • at least one of R ⁇ or R is present in Formula I.
  • the terminal amino acid of the pre or post-peptide that connects to the B-chain or A-chain comprises Arg or Lys.
  • the N-terminal multiple His-tagged Lis-Pro proinsulin construct comprises a 6-histidine (SEQ ID NO: 20) N-terminal tag and may have the sequence of MHHHHHHGGR (SEQ ID NO: 4).
  • the modified Lis-Pro proinsulin sequence may replace the native 24 amino acid pre-peptide with the 6-histidine (SEQ ID NO: 20) N-terminal tag sequence.
  • Rj and/or R ⁇ may be a sequence of one or more amino acids, e.g., preferably from 1 to 30 and more preferably from 6 to 10.
  • Native insulin comprises an A-chain having the sequence GIVEQCCTSICSLYQLENYCN (SEQ ID NO: 5) and a B-chain having the sequence FVNQHLCGSHLVEALYLVCGERGFFYTPKT (SEQ ID NO: 6).
  • the B-chain of Formula I is modified from native insulin and contains at least one amino acid mutation, substitution, deletion, insertion, and/or addition.
  • B 28 and B 2 of the B-chain are modified.
  • the lysine B29 of native insulin is substituted with proline and the proline B 28 of native insulin is substituted with lysine.
  • the B-chain that is modified is human insulin B-chain.
  • the B-chain that is modified is porcine insulin B-chain.
  • connecting peptide or "C- peptide” is meant the connecting moiety "C" of the B-C-A polypeptide sequence of a single chain Lis-Pro proinsulin molecule.
  • the N-terminus of the C- peptide connects to C-terminus of the modified B-chain, e.g., position 30 of the B-chain, and the C-terminus of the C-peptide connects to N-terminus of the A-chain, e.g., position 1 of the A- chain.
  • the C-peptide may have a sequence of formula II:
  • R 2 , R 3 , R 4 , R 5 , and X have the same meaning as in Formula I.
  • X may be a sequence having up to 40 amino acids, preferably up to 35 amino acids or more preferably up to 30 amino acids.
  • the C-peptide sequences of the present invention may include:
  • AR cannot be replaced with KR or RR.
  • Preferred modified Lis-Pro proinsulin sequences of the present invention may include: [0061] (l)FV QHLCGSHLVEALYLVCGERGFFYTKPTRREAEDLQVGQVELGGGPG
  • the single chain Lis-Pro insulin analogs of the invention will include three (3) correctly positioned, disulphide bridges, as is characteristic of the native human insulin.
  • the folded modified Lis-Pro proinsulin, or Lis-Pro proinsulin derivative peptide may include three (3) correctly positioned, disulphide bridges.
  • the C-peptide of the Lis-Pro proinsulin derivative peptide is removed to produce the Lis-Pro insulin analog.
  • Lis- Pro insulin analogs of the invention have a sequence (SEQ ID NOS 5 and 18, respectively, in order of appearance) of formula III, where the disulphide bridges are represented as -S-S-:
  • the present invention provides modified Lis-Pro proinsulin sequences having the modified C-peptide and methods for using these in a process to provide high yields of mature recombinant Lis-Pro insulin analog.
  • the positioning of these particular terminal amino acids in the C-peptide may provide for an improved method for producing recombinant Lis-Pro insulin analog, having fewer steps, improved yields of the recombinant Lis-Pro insulin analog and less contaminating byproducts.
  • insulin precursor or "proinsulin” are described as a single-chain polypeptide in which, by one or more subsequent chemical and/or enzymatic processes, may be converted into human insulin or insulin analog.
  • a proinsulin analog or modified proinsulin is defined as a proinsulin molecule having one or more mutations, substitutions, deletions, and or additions, of the A, B and/or C chains relative to the native human proinsulin nucleic acid sequence.
  • the Lis-Pro proinsulin analogs are preferably such wherein one or more of the naturally occurring nucleic acids have been substituted with another nucleic acid within a triplet encoding for a particular amino acid.
  • proinsulin analog is understood to refer to Lis-Pro proinsulin analog, unless otherwise specified.
  • insulin analog includes insulin molecules having one or more mutations, substitutions, deletions, additions, or modifications to one or more amino acids of a native insulin sequence.
  • the native insulin sequence is porcine insulin, while in another embodiment, the native insulin sequence is human.
  • insulin analog is understood to refer to Lis-Pro insulin analog, unless otherwise specified.
  • the term "about” is intended to be inclusive of and to encompass both an exact amount as well as an approximate amount or range of values or levels of the item, ingredient, element, activity, or other feature or characteristic to which it references. Generally, and in some embodiments, the term “about” is intended to reference a range of values relatively close to the specific numerical value specifically identified. For example, “about 3 grams to about 5 grams” is intended to encompass a measure of in or around a value of 3 grams, concentration values between 3 grams and 5 grams, concentration values in and around 5 grams, as well as concentration values that are exactly 3 grams and exactly 5 grams.
  • a high protein concentration of the Lis- Pro proinsulin or insulin analog product is defined as a protein yield concentration of at least about 3 grams/liter, or between about 3 grams to about 5 grams per liter.
  • the expression yield to be expected may be defined as a protein/peptide yield that is sufficient to detect via polyacrylamide gel electrophoreses (PAGE).
  • the invention provides a processes for producing highly purified Lis-Pro insulin analog that is more efficient than current techniques.
  • the invention in a general and overall sense relates to an improved process for preparing a heterologous recombinant protein in a prokaryotic host cell. This process is characterized in that it employs a recombinant Lis-Pro insulin protein that provides a useful and efficiently processed modified proinsulin sequence analog as described above.
  • heterologous protein is intended to mean that the protein in the prokaryotic host cell is not native, i.e., it occurs as a protein in peculiar or foreign (i.e., not native to) the host prokaryotic cell.
  • recombinant is intended to mean produced or modified by molecular- biological methods.
  • a recombinant protein is made using genetic engineering techniques and is not found in nature.
  • heterologous recombinant protein is defined as any protein known to the skilled person in the molecular biological arts, such as, for example, insulin, insulin analog, proinsulin, proinsulin analog, C-peptide, and proteins containing these together with any other protein or peptide fragment.
  • Prokaryotic host cells may be any host cells known to the skilled artisan in the molecular biological arts, and by way of example, Escherichia coli. Such types of cells available form public collections and useful in the practice of the present invention include, by way of example, the Deutsche Sammlung von Mikrooganismen and Zellkulturen GmbH, raunschweig, Germany, e.g., E. coli Strain K12 JM107 (DSM 3950).
  • the following reference table, Table 1 provides the triplet codons corresponding to each of the various amino acids that are used in the description of the present invention.
  • the amino acid that may be used in any particularly defined position as part of any of the peptide, protein, or constructs otherwise defined herein by reference to a particular nucleotide triplet base pair may be encoded by a number of different nucleotide triplets that function to encode the same amino acid.
  • the amino acid of the sequence defined herein is alanine (Ala, or A)
  • the triplet codon of nucleic acids that may encode for this amino acid are: GCT, GCC, GCA, or GCG.
  • the following table illustrates this definition of variables at and substitutions as can be applied to all of the naturally occurring amino acids sequences of the disclosure.
  • the Lis-Pro insulin analog prepared by the present invention may be formulated as liquid Lis-Pro insulin analog or crystalline Lis-Pro insulin analog.
  • a preparation of recombinant liquid Lis-Pro insulin analog is in a substantially liquid form and that has not been through a crystallization process. Eliminating these steps has no negative impact on the purity of the liquid Lis-Pro insulin analog produced, but has the added advantage of reducing the amount of inactive insulin multimers in the liquid Lis-Pro insulin analog of the invention.
  • Lis-Pro insulin analog reconstituted from lyophilized and crystallized insulin may be contaminated with inactive insulin multimers and is less preferred.
  • the methods of producing Lis-Pro insulin analog described herein generally include the following steps: fermentation/expression, Inclusion body isolation, solubilization of Lis-Pro proinsulin analog; refolding processing and transformation of Lis-Pro proinsulin analog to Lis-Pro insulin analog; and purification of Lis-Pro insulin analog.
  • FIGS. 2 A and 2B illustrate flow charts of preferred process steps in producing Lis-Pro insulin analog according to embodiments of the present invention.
  • the recombinant expression system is a transformed E. coli containing a Lis-Pro proinsulin analog expression vector.
  • the transformed cells may be vertebrate or invertebrate cells, such as prokaryote or eukaryote cells, and most preferably the cells may be mammalian, bacterial, insect, or yeast cells.
  • the cell is a bacterial cell and in a further embodiment, the bacteria is E. coli.
  • the cell is a yeast cell and in a further embodiment, the yeast cell is S. cerevisiae or S. pombe.
  • E. coli cells may be cultured and disrupted to provide a composition comprising inclusion bodies.
  • the inclusion bodies contain the modified Lis-Pro proinsulin sequence.
  • the Lis-Pro proinsulin analogs expressed by transformed E. coli cells according to the method of the invention may be secreted from the cells and include a secretory sequence.
  • Lis-Pro proinsulin analogs expressed by transformed cells are not secreted from the cells, and thus do not include a secretory sequence.
  • the step of solubilizing of the composition of inclusion bodies may involve adjusting the pH to achieve complete solubilization of the modified Lis-Pro proinsulin sequences.
  • the inclusion bodies may be solubilized by adjusting the pH to at least 10.5, preferably from 10.5 to 12.5, preferably from 11.8-12.
  • the pH may be adjusted by adding an alkali hydroxide such as NaOH or KOH to the composition of inclusion bodies.
  • the step of solubilization may use one or more reducing agents and/or chaotropic agent.
  • Suitable reducing agents may include those selected from the group consisting of 2-mercaptoethanol, L- cysteine hydrochloride monohydrate, dithiothreitol, dithierythritol, and mixtures thereof.
  • Suitable chaotropic agents include those selected from the group consisting of urea, thiourea, lithium perchlorate or guanidine hydrochloride, and mixtures thereof.
  • the solubilized inclusion bodies may be mixed in a refolding buffer, such as glycine or sodium carbonate, at a pH of 7-12, preferably from 10-11, preferably from 10.5-11, to refold the modified proinsulin sequences to a proinsulin derivative peptide, e.g., Lis-Pro proinsulin derivative peptide.
  • a refolding buffer such as glycine or sodium carbonate
  • the solution with refolded material should be pH adjusted to 7-9, preferably 7.8-8.2, with or without the addition of an alkaline salt, preferably sodium chloride to a final concentration of lOOmM to 1M final concentration, preferably 500mM - 1M, preferably 700mM, and may be filtered and loaded onto a column, such as an immobilized metal-ion affinity chromatography (IMAC) column.
  • an alkaline salt preferably sodium chloride
  • lOOmM to 1M final concentration preferably 500mM - 1M, preferably 700mM
  • IMAC immobilized metal-ion affinity chromatography
  • resins suitable for embodiments of the present invention include Nickle Sepharose 6 Fast Flow (GE Healthcare), Nickle NTA Agarose (GE Healthcare), Chelating Sepharose Fast flow(GE Healthcare), IMAC Fast Flow (GE Healthcare).
  • Lis-Pro proinsulin derivative peptide is subject to concentration by tangential flow filtration or diafiltration. Next, Lis-Pro proinsulin derivative peptide is enzymatically cleaved, preferred by subjecting the proinsulin derivative peptide to trypsin digestion.
  • embodiments of the present invention may use commercially available rat, bovine, porcine or human trypsins or other isoenzymes or derivatives or variants thereof, it is also possible to use the following enzymes: recombinant trypsin, trypzene, trypsin from Fusarium oxysporum and from Streptomyces (S. griseus, S. exfoliatus, S. erythraeus, S.
  • tryptase digestion occurs at a pH from about 7 to 10, and more preferably from 8.1 to 8.3.
  • the trypsin digest is quenched by adding an organic acid, preferably glacial acetic acid. While it is contemplated that other additives may be employed, acetic acid appears to be most preferred and stable for this purpose.
  • Trypsin is an enzyme that has specific cleavage activity at the terminal arginine residues, and to a lesser extent, lysine residues, of the C-peptide. In the transformation reaction, it is required that the terminal arginine or lysine residues of the C-peptide be removed. In native human proinsulin, when trypsin cleaves at the lysine in position 64, it will be unable to remove the arginine at position 65, due to the fact that it requires at least one residue on both sides of a cleavage site. What results is the production of an unwanted by-product, arg(A 0 )-insulin.
  • This by-product constitutes a small loss in yield and generates an undesired contaminant.
  • the level of arg(A 0 )-insulin byproduct is preferentially not formed. When formed is less than 10%, and more preferably is less than 0.3% of total byproducts from the trypsin transformation reaction may be arg(A 0 ). This is because the trypsin no longer acts to cleave at this particular site of the proinsulin derivative peptide.
  • the proinsulin derivative peptide may also be subjected to carboxypeptidase B digestion.
  • the Lis-Pro-proinsulin is double digested with trypsin and carboxypeptidase B in a glycine buffer at pH 9.6 ⁇ 0.1.
  • a trypsin inhibitor may be added to the insulin prior to addition of carboxypeptidase B. Trypsin inhibitor is added in an equal amount to the amount of trypsin added for the trypsin digest step.
  • a glycine solution is added to the DiR-Lis-Pro insulin analog prior to addition of carboxypeptidase B.
  • glycine is added to adjust the pH of the insulin solution to about 9.6 ⁇ 0.1.
  • the target concentration of glycine is 50mM using a 1M glycine stock.
  • the carboxypeptidase B is permitted to digest for at least 1-16 hours, preferably at least 8 hours. A minimum of 10 hours is preferred, but overdigestion is rarely a significant issue so there is no maximum time limit.
  • the intermediate DiR- Lis-Pro insulin is purified on a chromatography column, such as an ion exchange column or reverse phase chromatography column, prior to carboxypeptidase B digestion.
  • the Lis-Pro insulin material may be further purified using ion exchange or reverse phase chromatography.
  • the Lis-Pro insulin solution is preferably purified in a chromatography column, such as an ion exchange chromatography column or reverse phase chromatography column.
  • the intermediate solution may be purified in a chromatography column by eluting the Lis-Pro insulin analog using a buffer comprising an alcohol or organic solvent, preferably propanol, such as n-propanol.
  • the buffer may also further comprise an alkali metal salt, suchas sodium sulfate.
  • the buffer may also further comprise an organic acid, suchas phosphoric acid.
  • the amount of inactive insulin multimers present in the liquid formulation is reduced in comparison to the amounts otherwise present in crystallized forms of insulin and reconstituted crystallized insulin.
  • a crystallization step may be included to produce Lis-Pro insulin analog API crystals.
  • the Lis-Pro insulin analog may be crystallized to allow for increased shelf life to the API material.
  • the crystallization process may lead to increased levels of multimers and in turn an overall lower purity.
  • Lis-Pro insulin analog may prevent the formation of multimeric (non-monomeric) insulin, such as dimers and hexamers. Accordingly, upon administration of the Lis-Pro insulin analog to a patient, larger amounts of active monomeric insulin are available to act in the patient.
  • Lis-Pro insulin analog is particularly suitable for postprandial, i.e., after eating, injection as it is available immediately for use by the patient to control glucose levels. Accordingly, this analog has the advantage over native insulin in that its short delay of onset allows more flexibility with eating schedules for diabetic patients than regular insulin which requires a longer waiting period between injection and eating. According to one embodiment of the invention, the Lis-Pro insulin analog is provided to a patient in combination with a longer acting insulin to provide optimal glycemic control.
  • the preparations comprise a pharmaceutically acceptable preparation comprising recombinant Lis-Pro insulin analog and being essentially free of modified proinsulin sequences and/or non-monomeric Lis-Pro insulin molecules.
  • Step 1 Construction of a purified Lis-Pro proinsulin gene segment for insertion into the vector.
  • the initial gene construct was synthesized in a basic cloning vector (ptrcKis2a(Kan)).
  • the gene construct included the N-terminal histidine tag, MHHHHHHGGR (SEQ ID NO: 4), modified B-chain, and modified C-peptide with the alanine codon in place of the native lysine and having the amino acid sequence
  • Step 2 Generation of the pTrcHis2A(Kan) vector containing Lis-Pro proinsulin.
  • Commercially available pTrcHis2A(Kan) vector was modified to include a Kanamycin resistance gene in the middle of the Ampicillin resistance gene to negate the Ampicillin resistance prior to insertion of the proinsulin sequence into the vector.
  • Ampicillin resistance heightens the potential for allergic reactions to preparations made using vector constructs that include the Ampicillin resistance gene. Therefore it is preferable to eliminate the Ampicillin resistance in the constructs that are prepared and used.
  • the proinsulin gene was isolated from the DNA 2.0 plasmid using Ndel to cleave at the N-terminal side of the gene and EcoRl to cleave at the C-terminal side of the gene.
  • the Digested DNA was run over a 2% agarose gel to separate the plasmid DNA from the Lis-Pro proinsulin gene.
  • a QIAquickTM (Qiagen) gel purification kit was then used to purify the gene construct.
  • Step 3 Transformation.
  • One microliter of the ligation reaction was used to transform competent E. coli cells BL21 with the pTrcHis2A(Kan) plasmid containing the proinsulin gene.
  • the transformed E. coli BL21 cells were plated on LB-Kan agar plates and incubated overnight at 37°C. Several clones were selected and sequenced. Clones with the correct sequence were then screened for expression.
  • the resulting vector is referred to as the His Tagged Lis-Pro proinsulin pTrcHis2A(Kan) vector.
  • Step 4 Preparation of the working cell bank (WCB).
  • WCB working cell bank
  • sterile growth medium was inoculated with the recombinant BL21 E. coli containing the His Tagged Lis-Pro proinsulin pTrcHis2A(Kan) vector and incubated to allow cell growth.
  • the cells were harvested in an IS05 (class 100) environment under a biosafety cabinet via centrifugation. Sterile medium and glycerol were added to the cells. 1 mL aliquots of the cells were then dispensed into sterile ampoules and stored at -80°C. Aseptic techniques were utilized to generate a WCB.
  • Example 2 Product Manufacture of Lis-Pro Insulin Analog from Modified Proinsulin Sequence Carrying Transformed E. coli
  • Step 1 Culturing of E. coli transformed with Lis-Pro modified proinsulin sequence as described in Example 1. Seed an inoculum preparation of the transformed (WCB) in a sterile growth medium that includes yeastolate (purchased from VWR, Prod. # 90004-426 or - 488), select phytone, sodium chloride, purified water, sterile Kanamycin solution), and incubate until growth to an Optical density (OD 600 nm) of 2 to 4. Prepare a fermentation media (containing select phytone, yeastolate, glycerin, BioSpumex 153K (Cognis, Inc.) in a fermentor. Add the following sterilized phosphate solutions to the Fermentor.
  • Step 2 Disruption— Cells containing inclusion bodies expressing Lis-Pro modified proinsulin sequence are lysed in a basic Tris/salt buffer, using a Niro Soavi homogenizer (1100- 1200 bar).
  • Step 3 Inclusion Body Washing— Contaminant protein removal is accomplished via two sequential washes with a Tris/Triton X-100 buffer, followed by two sequential washes with a Tris/Tween-20 buffer, and finally a single wash with a Tris/NaCl buffer.
  • Step 4 - Solubilization Inclusion bodies enriched with the modified proinsulin peptide are solubilized in 4-8M urea, preferably 6-8M urea, containing reducing agents (2- mercaptoethanol, L-cysteine hydrochloride monohydrate). Complete solubilization is achieved by adjusting the pH to 10.5-12, preferably 11.8-12 with NaOH.
  • Step 5 Dilution refolding— The solubilized protein is then diluted into refolding buffer (20 mM Glycine, pH 10-11 at 6-10°C.) to a final concentration of 1 mg/ml and permitted to refold for 24 to 72 hours, preferentially about 48 hours, at 6-10°C. Higher protein concentration may be used in the refold if desired. However, overall refold efficiency will decrease.
  • Sodium Chloride and Phosphate are then added to final concentrations of 700 mM and 25 mM respectively, followed by pH adjustment to 7.0 to 9.0, preferably 7.9-8.0 with 6M HC1.
  • Step 6 IMAC Chromatography— The dilute proinsulin derivative is loaded onto an IMAC column to a maximum capacity of ⁇ 26.5 mg main peak protein per ml of resin. A 75mM imidizole buffer is used to isocratically strip the majority of impurities from the column. Lis-Pro proinsulin is eluted isocratically using ⁇ 300 mM imidizole.
  • Step 7 - Buffer exchange To the IMAC main peak pool material, add EDTA to a final concentration of 20 raM. Exchange the buffer using a membrane with a suitable molecular weight cutoff (e.g. 3000 Da). The final buffer should be at least 97% exchanged to a 20 mM Tris-Cl, pH 7.0-10.0, preferably 8.1 at 8-10°C. A protein concentration of approximately 5 mg/ml is desirable.
  • Step 8 Trypsin/Carboxypeptidase B Enzymatic Transformation/Proteolysis— The buffer exchanged sample is digested with a 1500: 1 mass ratio of main peak protein to trypsin and 1000:1 mass ratio of main peak protein to carboxypeptidase B, in the presence of 5mM CaCl. The ratios of trypsin and carboxypeptidase may be increased or decreased depending on the desired length of time for the reaction. Once complete, based on HPLC, the digest is then quenched by the addition of acetic acid to > 700 mM, to a pH of approximately 3-3.5.
  • step 8 in Example 2 the final purification may proceed using alternative processes in Examples 3 A or 3B.
  • Step 9a Ion Exchange Chromatography— The digested material is loaded onto a cation exchange column and eluted with a NaCl gradient, in the presence of 20% n-propanol or acetonitrile at pH 2-5, preferably 4.0. Fractions are diluted 1 :4 if n-propanol is used for elution or 1 :2 with cold purified water if acetonitrile is used for elution, or no dilution if acetonitrile is used for elution. RP-HPLC is used to pool the appropriate fractions containing the Lis-Pro insulin peak of interest at the desired purity level.
  • Step 10a Reverse Phase Chromatography— The S-column pool containing the Lis- Pro insulin is loaded onto an RPC30 or CI 8 reverse phase column and eluted using an n- propanol or acetonitrile gradient in the presence of 200mM sodium sulfate and 0.136% phosphoric acid. Fractions are immediately diluted 1 :4 with 1 OOmM phosphate buffer at pH 7.0- 9.0, preferably 7.5-8, as they are collected. RP-HPLC is used to pool the appropriate fractions containing the Lis-Pro Insulin peak of interest at the desired purity level.
  • Step 11a - Buffer Exchange Exchange the sample into WFI (water for injection) using a membrane with a suitable molecular weight cutoff (e.g. 3000 Da).
  • the pH of the solution should be monitored and maintained at 7.0-9.0, preferably 7.5-8.0.
  • the final sample is concentrated to 5.5-8 mg/ml, with an adjusted pH of 7.0-9.0, preferably 7.5-8.0at 6-10°C.
  • This material represents the liquid API form of the presently disclosed preparations of Lis-Pro Insulin Analog.
  • the API should be stored in the dark at 6-10°C.
  • Step 10b Reverse Phase Chromatography— The digested material containing the Lis-Pro insulin is loaded onto an RPC30 or CI 8 reverse phase column and eluted using a n- propanol or acetonitrile gradient in the presence of 200mM sodium sulfate and 0.136% phosphoric acid. Fractions are immediately diluted 1:4 with lOOmM phosphate buffer at pH 7.0- 9.0, preferably 7.5-8 as they are collected. RP-HPLC is used to pool the appropriate fractions containing the Lis-Pro insulin peak of interest at the desired purity level.
  • Step l ib - Buffer Exchange Exchange the sample into WFI using a membrane with a suitable molecular weight cutoff (e.g. 3000 Da).
  • the pH of the solution should be monitored and maintained at 7.0-9.0, preferably 7.5-8.0.
  • the final sample is concentrated to 5.5-5.8 mg/ml, with an adjusted pH of 7.5-8.0 at 6-10°C.
  • This material represents the liquid API form of the presently disclosed preparations and formulations of Lis-Pro Insulin Analog.
  • the Lis-Pro Insulin Analog purified by Examples 3A or 3B is formulated by diluting the API material with cold WFI to a final concentration of 4.3375 mg/ml.
  • a concentrated formulation buffer stock containing 80 mg/ml glycerol, 15.75 mg/ml meta cresol, and 0.0985 mg/ml zinc chloride at pH 7.5 ⁇ 0.1 is added to the API material in a 1/5 ratio of formulation buffer stock to API.
  • the solution is mixed, followed by sterile filtration into appropriate vials in 10 ml aliquots.
  • Example 1 The cloning procedure outlined in Example 1 is utilized to create the initial vector (transfection vector).
  • Purified His Tagged Lis-Pro proinsulin pTrcHis2A(Kan) vector is transformed into competent BL21 cells and plated on sterile LB- an plates. From the plates, an isolated colony is used to inoculate sterile LB-Kan media (-lOOmls). The cells are grown at 37°C to mid log phase (about 4-5 hours) OD 600nm of about 1.5-2.0. Culture media containing cells is then aliquoted into sterile cryovials, combined with glycerol at a 20% final concentration. The vials are then stored at 80°C.

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Diabetes (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Endocrinology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Obesity (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Hematology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • Emergency Medicine (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)

Abstract

La présente invention concerne des séquences de pro-insuline Lis-Pro qui présentent une séquence d'acide aminé C-peptide modifiée et/ou une modification d'acide nucléique. L'invention concerne également des procédés pour la production d'analogues de l'insuline Lis-Pro. L'invention concerne également des procédés hautement efficaces pour la préparation d'analogues de l'insuline Lis-Pro et des préparations améliorées contenant des analogues de l'insuline Lis-Pro préparés selon les procédés de la présente invention.
PCT/US2011/025934 2011-02-23 2011-02-23 Compositions de pro-insuline lis-pro et procédés de production d'analogues d'insuline lis-pro à partir de celles-ci WO2012115641A1 (fr)

Priority Applications (1)

Application Number Priority Date Filing Date Title
PCT/US2011/025934 WO2012115641A1 (fr) 2011-02-23 2011-02-23 Compositions de pro-insuline lis-pro et procédés de production d'analogues d'insuline lis-pro à partir de celles-ci

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PCT/US2011/025934 WO2012115641A1 (fr) 2011-02-23 2011-02-23 Compositions de pro-insuline lis-pro et procédés de production d'analogues d'insuline lis-pro à partir de celles-ci

Publications (1)

Publication Number Publication Date
WO2012115641A1 true WO2012115641A1 (fr) 2012-08-30

Family

ID=44262912

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2011/025934 WO2012115641A1 (fr) 2011-02-23 2011-02-23 Compositions de pro-insuline lis-pro et procédés de production d'analogues d'insuline lis-pro à partir de celles-ci

Country Status (1)

Country Link
WO (1) WO2012115641A1 (fr)

Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5474978A (en) 1994-06-16 1995-12-12 Eli Lilly And Company Insulin analog formulations
US5504188A (en) 1994-06-16 1996-04-02 Eli Lilly And Company Preparation of stable zinc insulin analog crystals
DE19605657A1 (de) * 1995-02-15 1996-08-22 Hanil Synthetic Fiber Co Ltd Proinsulinderivat und Verfahren zur Herstellung von menschlichem Insulin
US5700662A (en) 1989-02-09 1997-12-23 Eli Lilly And Company Process for preparing insulin analogs
US20010041787A1 (en) * 1999-12-29 2001-11-15 Kjeldsen Thomas Borglum Method for making insulin precursors and insulin precursor analogues having improved fermentation yield in yeast
US6777207B2 (en) 1999-12-29 2004-08-17 Novo Nordisk A/S Method for making insulin precursors and insulin precursor analogues having improved fermentation yield in yeast
US20100210815A1 (en) * 2006-12-13 2010-08-19 Elona Biotechnologies Insulin production methods and pro-insulin constructs

Patent Citations (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5700662A (en) 1989-02-09 1997-12-23 Eli Lilly And Company Process for preparing insulin analogs
US5474978A (en) 1994-06-16 1995-12-12 Eli Lilly And Company Insulin analog formulations
US5504188A (en) 1994-06-16 1996-04-02 Eli Lilly And Company Preparation of stable zinc insulin analog crystals
DE19605657A1 (de) * 1995-02-15 1996-08-22 Hanil Synthetic Fiber Co Ltd Proinsulinderivat und Verfahren zur Herstellung von menschlichem Insulin
US5962267A (en) 1995-02-15 1999-10-05 Hanil Synthetic Fiber Co., Ltd. Proinsulin derivative and process for producing human insulin
US20010041787A1 (en) * 1999-12-29 2001-11-15 Kjeldsen Thomas Borglum Method for making insulin precursors and insulin precursor analogues having improved fermentation yield in yeast
US6777207B2 (en) 1999-12-29 2004-08-17 Novo Nordisk A/S Method for making insulin precursors and insulin precursor analogues having improved fermentation yield in yeast
US20100210815A1 (en) * 2006-12-13 2010-08-19 Elona Biotechnologies Insulin production methods and pro-insulin constructs

Non-Patent Citations (6)

* Cited by examiner, † Cited by third party
Title
"Enzymes", 1979, E. C. LONGMAN GROUP LTD., pages: 261 - 262
CHAN ET AL., P.N.A.S., USA., vol. 78, 1981, pages 5401 - 5404
CHANG ET AL., BIOCHEM. J., vol. 329, 1998, pages 631 - 635
CHANG S-G ET AL: "HUMAN INSULIN PRODUCTION FROM A NOVEL MINI-PROINSULIN WHICH HAS HIGH RECEPTOR-BINDING ACTIVITY", BIOCHEMICAL JOURNAL, THE BIOCHEMICAL SOCIETY, LONDON, GB, vol. 329, 1 January 1998 (1998-01-01), pages 631 - 635, XP001037629, ISSN: 0264-6021 *
FRANK ET AL.: "Peptides: Proceedings of the 7th American Peptide Chemistry Symposium", 1981, PIERCE CHEMICAL COMPANY, pages: 721 - 728,729-
THIM ET AL., P.N.A.S., USA., vol. 83, 1986, pages 6766 - 6770

Similar Documents

Publication Publication Date Title
US7790677B2 (en) Insulin production methods and pro-insulin constructs
KR0150565B1 (ko) 유전자 조환에 의한 사람 인슐린 전구체의 제조 및 이를 이용한 인슐린의 제조방법
US8298789B2 (en) Orthogonal process for purification of recombinant human parathyroid hormone (rhPTH) (1-34)
CN112584853B (zh) 一种新型门冬胰岛素原的结构和制备门冬胰岛素的方法
JP2015083019A (ja) 精製生物活性異種タンパク質を得る方法
AU2009203810A1 (en) Novel insulin derivatives having an extremely delayed time-action profile
EP2307441B1 (fr) Procédé pour la fabrication de composés de l'insuline
WO2012115638A1 (fr) Compositions de pro-insuline glargine et procédés de production d'analogues de l'insuline glargine à partir de celles-ci
CN113105536A (zh) 一种新甘精胰岛素原及其制备甘精胰岛素的方法
US20160024168A1 (en) Aspart proinsulin compositions and methods of producing aspart insulin analogs
US20120214965A1 (en) Glargine proinsulin and methods of producing glargine insulin analogs therefrom
US10100098B2 (en) Insulin production methods and proinsulin constructs
US20110318779A1 (en) Process for producing recombinant protein using novel fusion partner
US20160039899A1 (en) Lis-pro proinsulin compositions and methods of producing lis-pro insulin analogs therefrom
US20160030520A1 (en) Liquid insulin compositions and methods of making the same
WO2012115640A1 (fr) Compositions liquides contenant de l'insuline et leurs procédés de fabrication
JP2021511785A (ja) 組換えポリペプチド生産用ｎ末端融合パートナーおよびこれを用いた組換えポリペプチドの生産方法
EP2502633A1 (fr) DNA pMSIN4 plasmidique recombinant, codant un polypeptide hybride - précurseur d'insuline humaine, souche E. coli BL21 (DE3) / pMSIN4 - producteur de l'insuline humaine recombinante, procédé pour la production d'insuline humaine recombinante
CS271191A3 (en) Enzymatic process of pre-proinsulins to insulins conversion
WO2012115641A1 (fr) Compositions de pro-insuline lis-pro et procédés de production d'analogues d'insuline lis-pro à partir de celles-ci
WO2012115637A1 (fr) Compositions de pro-insuline aspart et procédés de production d'analogues de l'insuline aspart
KR20190088916A (ko) 재조합 폴리펩타이드 생산용 n-말단 융합 파트너 및 이를 이용하여 재조합 폴리펩타이드를 생산하는 방법
US7514403B2 (en) Process for the stabilization of proteins in an aqueous solution comprising cysteine in a concentration between 150 and 220mM
WO2013149729A2 (fr) Proinsuline comprenant une séquence auxiliaire améliorée

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 11714444

Country of ref document: EP

Kind code of ref document: A1

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 11714444

Country of ref document: EP

Kind code of ref document: A1